公开(公告)号：US20240009287A1

公开(公告)日：2024-01-11

申请号：US18234935

申请日：2023-08-17

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Ravid STRAUSSMAN ,  Oded SANDLER ,  Reut RIFF

IPC: A61K39/00 ,  A61P35/00

CPC classification number: A61K39/0011 ,  A61P35/00 ,  A61K2039/52 ,  A61K2039/6006 ,  A61K2039/627

Abstract: A vaccine comprising a pharmaceutically acceptable carrier and bacteria which presents at least one cancer-associated antigen is disclosed. The bacteria are not genetically modified to express the at least one cancer-associated antigen. Uses thereof are also disclosed.

公开(公告)号：US20240197746A1

公开(公告)日：2024-06-20

申请号：US18589576

申请日：2024-02-28

Applicant: Yeda Research and Development Co. Ltd. ,  The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center

Inventor： Ravid STRAUSSMAN ,  Nancy GAVERT ,  Yaara ZWANG

IPC: A61K31/52 ,  A61K31/4184 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/513 ,  A61K31/517 ,  A61P35/00 ,  C12N5/071 ,  C12N5/09 ,  G01N33/50

CPC classification number: A61K31/52 ,  A61K31/4184 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/513 ,  A61K31/517 ,  A61P35/00 ,  C12N5/0679 ,  C12N5/0693 ,  G01N33/5011 ,  C12N2500/02 ,  C12N2527/00 ,  G01N2333/9121

Abstract: A method of treating colorectal cancer (CRC) is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a Mitogen/extracellular signal-regulated kinase (MEK) inhibitor and a SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase (SRC) inhibitor, wherein cancer cells of the subject express an amount of SRC p419 above a predetermined level and do not express a KRAS G12 mutation, thereby treating the CRC.

公开(公告)号：US20240133870A1

公开(公告)日：2024-04-25

申请号：US18530406

申请日：2023-12-06

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Ravid STRAUSSMAN ,  Oded SANDLER

IPC: G01N33/50

CPC classification number: G01N33/5011 ,  G01N33/5088

Abstract: Combined treatment for cancer is provided. Accordingly, there is provided a method of selecting or determining therapeutic efficacy of a combination of agents for the treatment of cancer in a subject in need thereof, the method comprising: (i) culturing a cancerous tissue of the subject in an ex-vivo organ culture (EVOC) in the presence of a combination of an anti-cancer agent and an additional agent, said additional agent is inhibiting expression and/or activity of a target conferring innate resistance to said anti-cancer agent or increasing expression and/or activity of a target conferring innate sensitivity to said anti-cancer agent; and (ii) determining an anti-cancer effect of the combination on the tissue, wherein responsiveness of the tissue to the combination indicates the combination is efficacious for the treatment of the cancer in the subject. Also provided are methods of treating cancer with a combination of agent wherein cancerous tissue obtained from the subject demonstrates responsiveness to the combination of agents in an ex-vivo organ culture (EVOC).

公开(公告)号：US20240009286A1

公开(公告)日：2024-01-11

申请号：US18234902

申请日：2023-08-17

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Ravid STRAUSSMAN ,  Oded SANDLER ,  Reut RIFF

IPC: A61K39/00 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K39/0011 ,  A61K39/3955 ,  A61P35/00 ,  A61K2039/523 ,  A61K2039/522

Abstract: A vaccine comprising tumor-homing bacteria which are genetically modified to express at least one cancer-associated antigen and a pharmaceutically acceptable carrier is disclosed. Uses thereof are also disclosed.

公开(公告)号：US20230203594A1

公开(公告)日：2023-06-29

申请号：US17958516

申请日：2022-10-03

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Ravid STRAUSSMAN ,  Noam SHENTAL ,  Ilana LIVYATAN ,  Deborah GITTA ROSENBERG NEJMAN ,  Garold FUKS

IPC: C12Q1/6886 ,  C12Q1/689

CPC classification number: C12Q1/6886 ,  C12Q1/689 ,  C12Q1/6869

Abstract: A method of treating cancer in a subject is disclosed. The method comprises:

(a) analyzing for the abundance of at least one bacteria in the tumor microbiome of the subject; and
(b) administering to the subject a therapeutically effective amount of an immunotherapy treatment on the basis of the abundance of said at least one bacteria.